Table 3 Subgroup analysis of studies from China and outside China
From: Clinical features and outcomes of COVID-19 in older adults: a systematic review and meta-analysis
Variable | China | Outside China | p-value for interaction | ||||
|---|---|---|---|---|---|---|---|
Number of studies/patients | Prevalence (95% CI) | p-value (Cochran’s Q); I2 | Number of studies/patients | Prevalence (95% CI) | p-value (Cochran’s Q); I2 | ||
Death | 16/2035 | 0.15 (0.05–0.26) | 0.00; 96% | 14/10025 | 0.11 (0.03–0.20) | 0.00; 98% | 0.56 |
≥1 comorbidity | 6/410 | 0.68 (0.53–0.82) | 0.00; 85% | 6/1478 | 0.84 (0.72–0.95) | 0.00; 91% | 0.09 |
Hypertension | 11/1387 | 0.42 (0.28–0.57) | 0.00; 91% | 6/858 | 0.57 (0.39–0.74); | 0.00; 81% | 0.20 |
Diabetes Mellitus | 10/921 | 0.22 (0.10–0.36); | 0.00; 90% | 7/883 | 0.22 (0.12–0.33) | 0.01; 65% | 1.00 |
Cardiovascular disease | 9/901 | 0.14 (0.08–0.20) | 0.00; 72% | 4/778 | 0.26 (0.11–0.43) | 0.00; 79% | 0.17 |
Chronic Lung disease | 9/883 | 0.07 (0.04–0.11) | 0.02; 56% | 6/865 | 0.08 (0.00–0.26) | 0.00; 91% | 0.88 |
Malignancy | 7/702 | 0.05 (0.03–0.07) | 0.30; 17% | 5/774 | 0.13 (0.01–0.28) | 0.00; 78% | 0.25 |
Kidney disease | 8/720 | 0.04 (0.01–0.07) | 0.06; 48% | 6/871 | 0.06 (0.00–0.18) | 0.00; 87% | 0.68 |
Liver disease | 6/582 | 0.02 (0.00–0.06) | 0.02; 62% | 5/834 | 0.04 (0.01–0.07) | 0.09; 50% | 0.85 |
Fever | 6/583 | 0.85 (0.56–1.00) | 0.00; 95% | 5/199 | 0.77 (0.67–0.87) | 0.08; 58% | 0.42 |
Cough | 6/583 | 0.57 (0.47–0.67) | 0.03; 61% | 5/199 | 0.71 (0.61–0.81) | 0.11; 12.47% | 0.05 |
Dyspnoea | 6/583 | 0.36 (0.07–0.68) | 0.00; 95% | 5/199 | 0.63 (0.45–0.80) | 0.00; 78% | 0.13 |